Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

341. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. (Abstract)

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. End-stage renal disease substantially increases the risks of death, cardiovascular disease, and use of specialized health care, but the effects of less severe kidney dysfunction on these outcomes are less well defined.We estimated the longitudinal glomerular filtration rate (GFR) among 1,120,295 adults within a large, integrated system of health care delivery in whom serum creatinine had been measured (...) , community-based population. These findings highlight the clinical and public health importance of chronic renal insufficiency.Copyright 2004 Massachusetts Medical Society

2004 NEJM

342. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. (Abstract)

estimated rather than measured glomerular filtration rate.During the period examined, growth in incident ESRD outpaced growth in prevalent chronic renal insufficiency, demonstrating that the ESRD epidemic in the United States is not merely a function of more cases of kidney disease. Future research should examine other potential contributors to ESRD growth, such as improved survival from nonrenal diseases and more liberal entry into treatment programs. (...) The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. The steady increase in end-stage renal disease (ESRD) incidence is a worldwide public health crisis.To determine whether the increasing incidence of ESRD in the United States is preceded by increased prevalence of chronic renal insufficiency.Birth cohort analysis.Nationally representative Second and Third National Health and Nutrition Examination Surveys (NHANES II [1976-1980

2004 Annals of Internal Medicine

343. The metabolic syndrome and chronic kidney disease in U.S. adults. (Abstract)

The metabolic syndrome and chronic kidney disease in U.S. adults. The metabolic syndrome is a common risk factor for cardiovascular disease.To examine the association between the metabolic syndrome and risk for chronic kidney disease and microalbuminuria.Cross-sectional study.The Third National Health and Nutrition Examination Survey.Participants 20 years of age or older were studied in the chronic kidney disease (n = 6217) and microalbuminuria (n = 6125) analyses.The metabolic syndrome (...) with the metabolic syndrome compared with participants without the metabolic syndrome were 2.60 (95% CI, 1.68 to 4.03) and 1.89 (CI, 1.34 to 2.67), respectively. Compared with participants with 0 or 1 component of the metabolic syndrome, participants with 2, 3, 4, and 5 components of chronic kidney disease had multivariate-adjusted odds ratios of 2.21 (CI, 1.16 to 4.24), 3.38 (CI, 1.48 to 7.69), 4.23 (CI, 2.06 to 8.63), and 5.85 (CI, 3.11 to 11.0), respectively. The corresponding multivariate-adjusted odds

2004 Annals of Internal Medicine

344. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. (Abstract)

The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Risk for coronary heart disease is high among patients with chronic kidney disease.To compare the prevalence of low apolipoprotein A1 levels and elevated apolipoprotein B, plasma fibrinogen, lipoprotein(a), homocysteine, and C-reactive protein levels by estimated glomerular filtration rate (GFR).Cross-sectional study.Third National Health and Nutrition Examination survey.12 547 (...) , 3180, and 744 persons with estimated GFRs of at least 90, 60 to 89, or less than 60 mL/min per 1.73 m2, respectively, who were at least 18 years of age.Chronic kidney disease was defined as an estimated GFR of less than 60 mL/min per 1.73 m2 based on the abbreviated Modification of Diet in Renal Disease formula.After standardization for age, race or ethnicity, and sex, lower estimated GFR (> or =90, 60 to 89, or <60 mL/min per 1.73 m2) was associated with lower average levels of apolipoprotein A1

2004 Annals of Internal Medicine

345. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials

A, Sarnak M J CRD summary This systematic review concluded that N-acetylcysteine is effective in the prevention of renal contrast nephropathy in patients with pre-existing chronic kidney disease. Although there were some limitations of the review in terms of measures taken to minimise reviewer bias and possible statistical diversity, overall, the authors' conclusions appear reliable. Authors' objectives To assess the effects of N-acetylcysteine (NAC) in the prevention of renal contrast nephropathy (RCN (...) Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials Alonso A, Lau J, Jaber B L, Weintraub

2004 DARE.

346. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. (Abstract)

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease. Current evidence suggests that some of these adverse outcomes can be prevented or delayed (...) by early detection and treatment. Unfortunately, chronic kidney disease is underdiagnosed and undertreated, in part as a result of lack of agreement on a definition and classification of its stages of progression. Recent clinical practice guidelines by the National Kidney Foundation 1) define chronic kidney disease and classify its stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of kidney disease, 3) associate the level of kidney function

2003 Annals of Internal Medicine

347. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. Full Text available with Trip Pro

Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. Previous research suggests that environmental lead exposure correlates with age-related decreases in renal function.Two hundred two patients with chronic renal insufficiency (indicated by a serum creatinine level between 1.5 mg per deciliter and 3.9 mg per deciliter) who had a normal total-body lead burden and no history of exposure to lead were observed for 24 months. After the observation (...) than that in the controls during the 24-month period of repeated chelation therapy or placebo.Low-level environmental lead exposure may accelerate progressive renal insufficiency in patients without diabetes who have chronic renal disease. Repeated chelation therapy may improve renal function and slow the progression of renal insufficiency.Copyright 2003 Massachusetts Medical Society

2003 NEJM Controlled trial quality: uncertain

348. The timing of specialist evaluation in chronic kidney disease and mortality. (Abstract)

The timing of specialist evaluation in chronic kidney disease and mortality. Care for chronic renal failure involves management of complications and preparation for possible dialysis. Patients often are not evaluated by nephrologists in a timely manner.To identify factors associated with late evaluation by a nephrologist and to assess whether late evaluation is associated with worse survival once patients develop end-stage renal disease (ESRD).National prospective cohort study.81 dialysis (...) characteristics, and socioeconomic status in Cox proportional hazards regression analysis. After additional adjustment for such factors as the presence and severity of comorbid conditions, the association remained graded (hazard ratio, 1.2 [CI, 0.73 to 1.82] for patients evaluated at an intermediate point and 1.6 [CI, 1.04 to 2.39] for those evaluated late).Late evaluation of patients with chronic renal failure by a nephrologist is associated with greater burden and severity of comorbid disease, black

2002 Annals of Internal Medicine

349. Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. (Abstract)

Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition. Progression to renal parenchymal damage and end-stage renal disease, which seems to be largely independent of the initial insult, is the final common pathway for chronic, proteinuric nephropathies in animals and humans. The key event is enhanced glomerular capillary pressure; this impairs glomerular permeability to proteins and permits excessive amounts of proteins to reach the lumen of the proximal tubule (...) . Clinical data strongly suggest that remission can now be achieved in some patients with chronic renal disease. Because of the current lag time between starting treatment and remission, however, a substantial proportion of patients still progress to end-stage renal disease before renal function begins to stabilize. A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most

2002 Annals of Internal Medicine

350. Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. (Abstract)

Low protein diets delay end-stage renal disease in non diabetic adults with chronic renal failure. Since more than fifty years, low protein diets are proposed to patients with kidney failure. However, the effects of these diets in preventing severe renal failure and the need for maintenance dialysis is still controversial.To determine the efficacy of low protein diets in delaying the need to start maintenance dialysis.Medline and Embase search from January 1966 through June 1999. Congress (...) a reduced protein intake and 741 a larger protein intake. Collection of the number of "renal death" being the need for starting dialysis, the death of a patient or the transplantation of a kidney during the trials.242 renal deaths were recorded, 101 in the low protein diet and 141 in the larger protein diet group, giving an odds ratio of low protein to control of 0.62 with a 95% confidence interval of 0.46 to 0.83 (p<0.001, Peto odds ratio). To spare one extra renal death, 17 patients need to be treated

2000 Cochrane

351. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. (Abstract)

Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. The aim of this review is to assess the risks and benefits of diuretics acting on distal segments of the renal tubule (distal diuretics) in preterm infants with or developing chronic lung disease (CLD). Primary objectives are to assess changes in need for oxygen or ventilatory support and effects on long-term outcome, and secondary objectives are to assess changes in pulmonary mechanics (...) and potential complications of therapy.We used the standard method of the Cochrane Neonatal Review Group. We used the following keywords: ¿ or <chronic lung disease>¿ and , limited to and limited to or . We searched Medline (1966-1998), Embase (1974-1998) and the Cochrane Controlled Trials Register (CCTR) from the Cochrane Library (1999, issue 2). In addition, we hand searched several abstract books of national

2000 Cochrane

352. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials

across a spectrum of disease causes and renal dysfunction. Research: The authors do not report any research implications of the review. Funding Division of Nephrology and Hypertension, University of North Carolina. Bibliographic details Kshirsagar A V, Joy M S, Hogan S L, Falk R J, Colindres R E. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases 2000; 35(4): 695-707 PubMedID (...) Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials Kshirsagar A V, Joy M S, Hogan S L, Falk R J, Colindres R E Authors' objectives

2000 DARE.

353. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. Full Text available with Trip Pro

Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. To evaluate whether the protein:creatinine ratio in spot morning urine samples is a reliable indicator of 24 hour urinary protein excretion and predicts the rate of decline of glomerular filtration rate and progression to end stage renal failure in non-diabetic (...) patients with chronic nephropathy.Cross sectional correlation between the ratio and urinary protein excretion rate. Univariate and multivariate analysis of baseline predictors, including the ratio and 24 hour urinary protein, of decline in glomerular filtration rate and end stage renal failure in the long term.Research centre in Italy.177 non-diabetic outpatients with chronic renal disease screened for participation in the ramipril efficacy in nephropathy study.Rate of decline in filtration rate

1998 BMJ Controlled trial quality: uncertain

354. Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature)

Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature) Anthony D, Stevens A Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of growth hormone treatment in children with growth hormone deficiency (GHD), Turner's syndrome (TS), chronic renal failure (CRF) and idiopathic short stature (ISS). Type of intervention Treatment. Economic study type Cost-utility analysis

1996 NHS Economic Evaluation Database.

355. Growth hormone in children (for growth hormone deficiency, Turner's syndrome, chronic renal failure and idiopathic short stature)

and short stature in Turner's syndrome. It has recently been licensed for use by children with short stature due to chronic renal failure. The authors aim to examine how effective this treatment is, and whether it actually has any positive effects, medical or psychological. Authors' conclusions Almost all the trial results show an improvement in height for all children treated with growth hormone regardless of their growth disorder. This height improvement enables the majority of treated children (...) Analysis; Growth Disorders Growth Hormone; Kidney Failure, Chronic; Turner Syndrome Language Published English Country of organisation England Address for correspondence Pauline King. Wessex Institute for Health Research and Development, Boldrewood Medical School, Bassett Crescent East, Highfield, Southampton SO16 7PX. Tel. +44 1703 595661 Fax +44 1703 595662 AccessionNumber 31998008875 Date bibliographic record published 10/08/1998 Date abstract record published 10/08/1998 Health Technology Assessment

1996 Health Technology Assessment (HTA) Database.

356. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. (Abstract)

The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. Restricting protein intake and controlling hypertension delay the progression of renal disease in animals. We tested these interventions in 840 patients with various chronic renal diseases.In study 1, 585 patients with glomerular filtration rates of 25 to 55 ml per minute per 1.73 m2 of body-surface area were randomly assigned (...) in the glomerular filtration rate during the first four months after randomization and a slower decline thereafter. In study 2, the very-low-protein group had a marginally slower decline in the glomerular filtration rate than did the low-protein group (P = 0.07). There was no delay in the time to the occurrence of end-stage renal disease or death. In both studies, patients in the low-blood-pressure group who had more pronounced proteinuria at base line had a significantly slower rate of decline

1994 NEJM Controlled trial quality: uncertain

357. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. (Abstract)

Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. The control of hyperphosphatemia is a major clinical problem in patients with chronic renal failure receiving regular dialysis treatment. Despite continuing concern about aluminum toxicity, aluminum-containing antacids are still used in many of these patients as phosphate-binding agents. Although maximal acceptable doses of aluminum hydroxide have been recommended (...) than in those receiving calcium carbonate. The skeletal lesions of secondary hyperparathyroidism improved in 7 of 10 patients receiving calcium carbonate but persisted or progressed in 6 of 7 patients given aluminum hydroxide (P less than 0.025).Aluminum hydroxide is less effective than calcium carbonate as a phosphate-binding agent for the control of hyperphosphatemia and is associated with aluminum retention in children and young adults with chronic renal failure who are receiving dialysis

1991 NEJM Controlled trial quality: uncertain

358. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. (Abstract)

Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. We investigated whether the glomerular synthesis of prostacyclin modulates the renal blood flow and glomerular filtration rate in chronic glomerular disease. The urinary excretion of 6-keto-prostaglandin F1 alpha, a stable breakdown product of prostacyclin, was significantly (P less than 0.01) reduced in 20 women with chronic glomerular disease (...) ) to the basal urinary excretion of 6-keto-prostaglandin F1 alpha but not of prostaglandin E2. No functional changes were detected in five healthy women, despite a similar suppression of renal prostacyclin synthesis by ibuprofen. In contrast, one week of treatment with sulindac did not affect renal prostacyclin synthesis or renal function in the other 10 patients, despite a marked inhibition of extrarenal cyclooxygenase activity. We conclude that in patients with mild impairment of renal function, the renal

1984 NEJM Controlled trial quality: uncertain

359. Cost effectiveness analysis applied to the treatment of chronic renal disease

renal disease. Medical Care 1968; 6(1): 48-54 Indexing Status Subject indexing assigned by CRD MeSH Cost-Benefit Analysis; Hemodialysis Units, Hospital /economics; Hemodialysis, Home /economics; Hospitalization /economics; Kidney Failure, Chronic /therapy; Kidney Transplantation /economics; Treatment Outcome AccessionNumber 21995005212 Date bibliographic record published 09/08/1996 Date abstract record published 09/08/1996 NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews (...) Cost effectiveness analysis applied to the treatment of chronic renal disease Cost effectiveness analysis applied to the treatment of chronic renal disease Cost effectiveness analysis applied to the treatment of chronic renal disease Klarman H E, Francis J O, Rosenthal G D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed

1968 NHS Economic Evaluation Database.